Cargando…
What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF study in 2014. Therefore, for patients...
Autores principales: | Badreldin, Hisham A., Aldosari, Nasser, Alnashwan, Lama, Almutairi, Taif, Yousif, Nada, Alsulaiman, Khalid, Aljuhani, Ohoud, Hafiz, Awatif, Alshaya, Omar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875386/ https://www.ncbi.nlm.nih.gov/pubmed/35200707 http://dx.doi.org/10.3390/jcdd9020054 |
Ejemplares similares
-
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021) -
Clinical Pharmacy Faculty Provision of Direct Patient Care, Challenges, and Opportunities
por: Korayem, Ghazwa B., et al.
Publicado: (2023) -
Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021) -
Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019) -
Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)